Dr. Mazzo currently is Non-Executive Chairman of Psivida, Inc. and a Director of Avanir Pharmaceuticals. He earned a Bachelor of Arts degree in the Honors Program (Interdisciplinary Humanities) and a Bachelor of Science degree in Chemistry from Villanova University. In addition, Dr. Mazzo received his Master of Science degree in Chemistry and his Ph.D. degree in Analytical Chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.
About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic field with the discovery and development of drug:antidote systems. These systems comprise aptamer therapeutics that can be directly controlled by a specific and matched oligonucleotide agent. Regado's technology is designed to give physicians the ability to directly control and fine tune each product's therapeutic effect. This control and flexibility allows physicians to meet the individual needs of each patient independent of the setting. A spin-out of the Department of Surgery at Duke University Medical Center, Regado was created to answer the therapeutic needs identified by its scientific founders and clinical advisors.
The Company's proprietary platform technology enables the discovery of oligonucleotide-based drug-modulating pairs to any target protein. Regado initially is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles.
Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.
|SOURCE Regado Biosciences|
Copyright©2008 PR Newswire.
All rights reserved